Stakeholders: Clarity Needed On FDA's Use Of Patient Engagement Data

September 25, 2015 at 10:32 AM
A group of stakeholders called for FDA to provide greater clarity on its policies for incorporating patient engagement into the drug review process. At this point, the pharmaceutical industry is hesitant to implement patient engagement strategies due to ambiguity surrounding the regulatory framework, they said. The press for clarity from FDA comes as patient groups, researchers and drug manufacturers seek a streamlined approach for incorporating the patient voice in the drug development process. Stakeholders are calling for development of a...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.